NCT00818298View on ClinicalTrials.gov

24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

June 30, 2011

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

ziprazidone

Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health - PET Centre, Toronto

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Centre for Addiction and Mental Health

OTHER